BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director John Schmid acquired 6,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $96,000.00. Following the completion of the acquisition, the director directly owned 6,000 shares in the company, valued at approximately $96,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
BlossomHill Therapeutics Price Performance
Shares of NASDAQ BLSM traded down $0.01 during trading hours on Monday, reaching $15.99. 417,968 shares of the stock traded hands. BlossomHill Therapeutics, Inc. has a 52-week low of $15.25 and a 52-week high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
